Biogen: Immunology serves as a new growth driver - JPMorgan upgrades assessment to Overweight and price target to 300 USD!
Reading Time: 2 minutes
JPMorgan raises price target to 300 USD and rates with "Overweight". Data on Felzartamab and Litifilimab promise strong impulses in 2027. Strategy shift: Focus expands from neurology to immunology. Strategic realignment away from classical neurology Biogen (BIIB) , historically established as a pioneer in neurological diseases, is undergoing a profound transformation. Instead of primarily relying on the Alzheimer's drug Leqembi, the company is deliberately expanding its business model to include immunology and rare diseases. This strategic...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
